Angelman syndrome is a neurodevelopmental disorder typically recognized in early childhood (usually by age 1–3 years), caused by loss of function of the maternally inherited UBE3A gene on chromosome 15q, and characterized by severe intellectual disability, absent or minimal speech, ataxic movements, frequent seizures, and a characteristically happy demeanor with frequent smiling and laughter.

Exam domain	One-glance essentials
Definition / diagnosis	Neurodevelopmental disorder from loss of maternal UBE3A expression in brain ^[1] Deletion, paternal UPD, imprinting defect and pathogenic variants are causes ^[1]
Epidemiology / risks	Usually sporadic; recurrence varies greatly by molecular mechanism ^[1] Maternal UBE3A variants can confer high recurrence ^[1]
Core mechanism	Neuronal paternal UBE3A is silenced, leaving dependence on the maternal allele ^[1] Loss impairs synaptic development and plasticity ^[1]
Clinical picture	Severe speech impairment, ataxia, happy demeanour and microcephaly ^[1] Seizures and characteristic EEG abnormalities are common ^[1]
Investigations	Methylation analysis detects deletion, UPD and imprinting defects ^[2] Sequence UBE3A if methylation testing is normal but suspicion remains ^[2]
Management	Control seizures and provide communication, sleep and developmental therapies ^[3] Treat reflux, constipation, scoliosis and mobility problems ^[3]
Complications	Status epilepticus, aspiration and injury from ataxia ^[4] Sleep disturbance and scoliosis affect long-term function ^[4]
Prevention / follow-up	Genetic counselling must use the confirmed molecular mechanism ^[3] Safety planning and augmentative communication improve participation ^[3]
Exam traps	*Angelman is maternal loss; Prader-Willi is paternal loss at 15q11-q13* ^[2] A normal routine karyotype does not exclude Angelman syndrome ^[3]

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 498–500)

^[2] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 498–500)

^[3] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 498–500)

^[4] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 498–500)

Angelman Syndrome (AS) — Paediatric Genetics

Angelman syndrome (AS) (天使綜合症 / 快樂木偶症) is a neurogenetic disorder characterised by severe developmental delay, (near-)absence of speech, movement and balance disorder (ataxia), epilepsy, and a distinctive behavioural phenotype of frequent, unprovoked laughter and smiling with a happy disposition ^[1]^[2].

Breaking down the name:

Originally called "Happy Puppet Syndrome" by Harry Angelman (1965), who described three children with a stiff, jerky gait, absent speech, and excessive laughter — he renamed it Angelman syndrome because the original term was considered pejorative.
The underlying molecular defect involves loss of function of the maternally inherited UBE3A gene on chromosome 15q11.2-q13, a region subject to genomic imprinting ^[1]^[2]^[3].

Core Concept — Genomic Imprinting at 15q11-13

The 15q11-13 region is an imprinted locus: certain genes are expressed only from one parental allele and silenced on the other. UBE3A is paternally imprinted in the brain (i.e., only the maternal copy is expressed in neurons). Loss of the maternal copy therefore leaves the child with no functional UBE3A protein in the brain, causing Angelman syndrome. Conversely, loss of the paternal contribution at this same locus causes Prader-Willi syndrome — they are "sister" imprinting disorders ^[1]^[2]^[3].

Parameter	Detail
Incidence	~1 in 12,000 – 20,000 live births ^[1]
Sex ratio	M = F (no sex predominance) ^[1]
Ethnic distribution	All ethnicities equally affected
Hong Kong context	Rare but recognised; managed at specialised paediatric genetics / neurology services (e.g., QMH, PWH); exact local incidence data limited, but consistent with worldwide figures
Inheritance	Majority de novo (~70–80%); recurrence risk varies by mechanism (see Etiology) ^[1]^[2]

AS accounts for a significant proportion of cases of severe intellectual disability with epilepsy in paediatric populations.
Epilepsy occurs in up to 80–90% of patients with AS — making it one of the genetic aetiologies most strongly associated with seizures ^[4].

3. Anatomy and Function: The UBE3A Gene and the 15q11-13 Imprinted Region

Chromosome 15q11.2-q13 contains a cluster of imprinted genes critical for neurodevelopment.
This region spans ~6 Mb and contains:
- Genes expressed only from the paternal allele (e.g., SNRPN, NDN, MAGEL2 — loss → Prader-Willi syndrome)
- UBE3A: expressed biallelically in most tissues, but only from the maternal allele in neurons (paternally silenced in the brain via an antisense transcript, UBE3A-ATS) ^[1]^[2]^[3]

UBE3A encodes ubiquitin-protein ligase E3A (also called E6-AP) ^[1].
"Ubiquitin" comes from Latin ubique = "everywhere" — ubiquitin is a small protein found in virtually all cells.
UBE3A = Ubiquitin-protein ligase E3A:
- It functions as an E3 ubiquitin ligase in the ubiquitin-proteasome pathway.
- It marks other proteins for ubiquitination (tagging with ubiquitin chains) → targets them for proteasomal degradation ^[1].
- This is a key cellular housekeeping mechanism — removing misfolded, damaged, or no-longer-needed proteins.

In the brain, only the maternal allele of UBE3A is active (paternal allele is silenced by imprinting).
Loss of the maternal allele → no UBE3A protein in neurons → accumulation of substrate proteins that should have been degraded → disruption of:
- Synaptic function and synaptic plasticity (UBE3A substrates include proteins involved in synaptic signalling, e.g., Arc/Arg3.1)
- Neuronal excitability → lowered seizure threshold → epilepsy
- Dendritic spine morphology → impaired learning and memory
- GABAergic signalling — GABRA5, GABRB3, GABRG3 (GABA-A receptor subunit genes) are located in the 15q11-13 region; large deletions that remove these contribute to the seizure phenotype

Why the Brain is Specifically Affected

UBE3A is expressed biallelically (from both parents) in most body tissues, so losing one copy doesn't matter much peripherally. But in neurons, the paternal copy is silenced by imprinting — so there is no "backup." This neuron-specific monoallelic expression is why AS is primarily a neurological disorder.

Imprinting is regulated by epigenetic mechanisms — primarily DNA methylation at CpG islands within the imprinting control region (ICR) ^[2]^[3].
The PWS/AS ICR (also called the bipartite imprinting centre) on 15q11-13 controls the parent-of-origin-specific expression of genes in this cluster.
Mechanisms of epigenetics include: ^[2]
- DNA methylation: methylation → DNA more tightly bound → ↓expression
- Histone modification
- microRNA-mRNA interaction: microRNA degrades mRNA → ↓expression

4. Aetiology (Focus on Hong Kong / East Asian Populations)

Angelman syndrome is caused by deficiency of UBE3A ^[1]. Several molecular mechanisms can produce this:

Mechanism	Frequency	Recurrence Risk	Notes
De novo deletion of 15q11-13 (maternal)	~70–75%	< 1% (unless parental translocation)	Most common; typically ~5–7 Mb deletion; usually Class I (BP1–BP3) or Class II (BP2–BP3) breakpoint deletions
UBE3A point mutation	~10–20% (some sources ~10–11%)	Up to 50% if mother carries mutation	Missense, nonsense, frameshift, or splice-site mutations in UBE3A itself
Paternal uniparental disomy (UPD)	~2–5%	< 1%	Child inherits two copies of chromosome 15 from father, none from mother → no maternal UBE3A
Imprinting defect	~3–5%	Variable (up to 50% if inherited IC deletion)	Abnormal methylation of the maternal allele, causing it to adopt a "paternal" epigenetic pattern → silencing of maternal UBE3A
Unknown / no detectable abnormality	~10–15%	Empirical ~10%	Clinical diagnosis of AS but molecular testing negative; may involve regulatory elements or mosaicism

^[1]^[2]^[3]

High Yield: The mechanism matters for genetic counselling — deletions are usually de novo (low recurrence), but UBE3A point mutations can be inherited from the mother (up to 50% recurrence). Always determine the molecular mechanism before counselling the family.

Both syndromes involve the 15q11-13 imprinted region but affect different genes ^[1]^[2]^[3]:

Feature	Angelman Syndrome	Prader-Willi Syndrome
Gene affected	UBE3A (maternally expressed)	Paternal genes (SNRPN, NDN, MAGEL2, snoRNAs)
Parental origin of defect	Loss of maternal allele	Loss of paternal allele
Deletion	~70–75% (maternal deletion)	~60% (paternal deletion)
UPD	Paternal UPD (~2–5%)	Maternal UPD (~35%)
Point mutation	UBE3A mutation (10–20%)	< 5%
Similarities	Both → hypotonia, developmental delay, intellectual disability ^[2]
Key clinical difference	Severe ID, no speech, ataxia, epilepsy, happy demeanour	Hyperphagia, obesity, hypogonadism, mild-moderate ID
Methylation pattern	Only paternal (unmethylated) pattern detected ^[2]	Only maternal (methylated) pattern detected ^[2]

^[1]^[2]

Angelman syndrome is pan-ethnic; no specific increased prevalence in Chinese/Hong Kong populations.
Diagnosis may be delayed in Hong Kong (as elsewhere) because early features (hypotonia, feeding difficulty) are non-specific; the characteristic behavioural phenotype emerges after 1 year.
Genetic testing available at HA clinical genetics services includes methylation-specific MLPA/MS-PCR, FISH, chromosomal microarray, and UBE3A sequencing.
Antiepileptic drug selection is important — certain AEDs (carbamazepine, vigabatrin, phenytoin) can worsen seizures in AS (discussed in management section).

Angelman syndrome can be classified by molecular mechanism (which has implications for phenotype severity and recurrence risk):

Class	Molecular Mechanism	Phenotype Severity
Class I	Large deletion (Class I: BP1–BP3)	Most severe (additional genes in deletion, including GABA receptor genes → more severe epilepsy and cognitive impairment)
Class II	Smaller deletion (Class II: BP2–BP3)	Severe but slightly less than Class I
Class III	UBE3A point mutation	Moderate-severe; may have slightly better motor function
Class IV	Imprinting defect	Milder; some may develop limited speech
Class V	Paternal UPD	Milder; better motor function, less severe epilepsy
Class VI	Unknown / clinical diagnosis only	Variable

Genotype-Phenotype Correlation

Patients with large deletions tend to have the most severe phenotype because the deletion encompasses not only UBE3A but also neighbouring genes (e.g., GABRB3, GABRG3 → worse epilepsy; OCA2 → hypopigmentation). Patients with UPD or imprinting defects tend to be milder because UBE3A-adjacent genes are intact (just silenced by imprinting or absent in the maternal copy only).

6. Clinical Features

Neonatal / early infancy: Non-specific features (feeding difficulty, hypotonia) — often not diagnosed at this stage.
6–12 months: Developmental delay becomes apparent; seizures may begin.
1–3 years: The classic behavioural phenotype (happy disposition, unprovoked laughter) and movement disorder (ataxia) emerge, prompting clinical suspicion.
Features are age-dependent — evolve over childhood and adolescence.

6.2 Symptoms (What the Parents Report)

Symptom	Pathophysiological Basis
Severe developmental delay / global developmental delay	Loss of UBE3A → impaired synaptic plasticity, dendritic spine abnormalities → failure of normal neurodevelopment ^[1]
Learning difficulties: (near-)absence of speech	UBE3A loss particularly affects language centres; receptive language > expressive language (understand more than they can say) ^[1]
Motor milestone delay	Ataxia + truncal hypotonia + limb hypertonia → delayed walking (typically 3–5 years if achieved); broad-based, unsteady gait ^[1]
Feeding difficulty (infancy)	Feeding difficulty in early infancy; poor suck due to hypotonia and oromotor dysfunction ^[1]

Symptom	Pathophysiological Basis
Epilepsy	Up to 80–90% develop seizures, typically onset 1–3 years; multiple seizure types (myoclonic, atypical absence, generalised tonic-clonic, atonic); EEG shows characteristic high-amplitude slow-spike-and-wave pattern. Loss of UBE3A → neuronal hyperexcitability; deletion of GABA-A receptor genes (GABRB3/GABRG3) in large-deletion patients → further lowers seizure threshold ^[1]^[4]
Seizures provoked by fever	AS children have a very low seizure threshold; febrile seizures are common and may be the first seizure type

High Yield: Epilepsy in Angelman syndrome can be very difficult to control and is often the most challenging management issue. Certain AEDs can paradoxically worsen seizures (carbamazepine, vigabatrin, phenytoin, tiagabine — all can exacerbate myoclonic and absence seizures).

Symptom	Pathophysiological Basis
Happy disposition: unprovoked, prolonged laughter and smiling	Hypothesised to be due to altered dopaminergic/serotonergic signalling in mesolimbic reward circuits secondary to UBE3A deficiency ^[1]
Easily excited, hypermotoric, hyperactive	Impaired inhibitory (GABAergic) signalling → reduced behavioural inhibition ^[1]
Short attention span	Same mechanism as above
Sleep disorder	Very common (~80%); reduced total sleep time, frequent night-time awakenings; likely due to abnormal melatonin secretion (↓melatonin levels documented in AS) ^[1]
Hand flapping / stereotypic movements	Self-stimulatory behaviours; also related to the "excitable" phenotype
Fascination with water	Classic behavioural quirk described in AS (mechanism unclear)

Symptom	Pathophysiological Basis
Drooling / excessive salivation	Oromotor dysfunction (hypotonia of oropharyngeal muscles)
Mouthing behaviours	Oral sensory-seeking; also related to intellectual disability
Constipation	Hypotonia of GI smooth muscle; possibly related to hypomotility

6.3 Signs (What You Find on Examination)

Sign	Pathophysiological Basis
Microcephaly	Postnatal-onset (head circumference usually normal at birth but decelerates by 2 years); reflects reduced brain growth due to impaired neuronal development; absolute or relative microcephaly ^[1]
Brachycephaly	Short, broad head shape; associated with the overall craniofacial dysmorphism ^[1]
Deep-set eyes	Facial dysmorphism pattern
Macrostomia (wide mouth) with protruding tongue	Facial dysmorphism + oromotor hypotonia → tongue protrusion ^[1]
Widely-spaced teeth	Part of facial gestalt
Prominent chin (prognathia)	Becomes more apparent with age — "coarsening" of facial features over time ^[1]
Hypopigmentation of skin, eyes, hair	In deletion patients: the OCA2 gene (oculocutaneous albinism type 2) lies within the commonly deleted region → reduced melanin production → fair skin/hair/eyes relative to family members ^[1]

Hypopigmentation — Only in Deletion Patients

Hypopigmentation (fair hair, light skin compared to family) is present predominantly in patients with the deletion mechanism because the OCA2 gene (which encodes a melanosomal transmembrane protein involved in melanin biosynthesis) is located within the commonly deleted 15q11-13 segment. Patients with UPD, imprinting defects, or UBE3A point mutations usually have normal pigmentation for their ethnicity. This is a classic genotype-phenotype correlation.

Sign	Pathophysiological Basis
↓ Trunk muscle tone (truncal hypotonia)	Central hypotonia from UBE3A loss → impaired descending motor pathway modulation of axial musculature ^[1]
↑ Arms/legs muscle tone (limb hypertonia) ± hyperreflexia	Upper motor neuron-type pattern; spasticity develops over time, especially in lower limbs; reflects cortical/subcortical motor circuit dysfunction ^[1]
Ataxia (early feature)	Cerebellar dysfunction — UBE3A is highly expressed in Purkinje cells; loss → impaired cerebellar output → wide-based, unsteady, "puppet-like" gait with arms raised and flexed ("air-plane" posture) ^[1]
Tremulous movements of limbs	Fine tremor, especially with intentional movements; cerebellar origin
Severe intellectual disability	Measured IQ usually < 40; reflects profound synaptic dysfunction across cortical networks ^[1]
Absent or minimal speech	Only a few words at most in majority; better nonverbal/gestural communication; reflects dominant hemisphere language circuit dysfunction

High Yield — The "Puppet-Like" Gait: The characteristic gait of Angelman syndrome — wide-based, stiff-legged, arms held up and flexed, with jerky movements — is due to the combination of truncal ataxia (cerebellar) + lower limb spasticity (upper motor neuron). This gave rise to the original (now deprecated) name "Happy Puppet Syndrome."

Characteristic EEG pattern seen in > 80% of AS patients, often present before clinical seizures manifest:
- High-amplitude rhythmic delta activity (2–3 Hz), most prominent over frontal regions
- Intermittent runs of rhythmic theta activity (4–6 Hz), especially posteriorly
- Epileptiform discharges facilitated by eye closure
- These patterns are highly suggestive of AS and can be a diagnostic clue even in infancy

Parameter	Finding
Birth weight / length	Usually normal
Postnatal growth	Generally normal linear growth (not short stature, unlike PWS)
Head circumference	Microcephaly — postnatal deceleration (crosses centiles downward by age 2)
BMI	Variable; some patients develop obesity in adolescence/adulthood; not a defining feature

Sign	Pathophysiological Basis
Scoliosis	Truncal hypotonia → poor paraspinal muscle support → progressive thoracolumbar scoliosis; worsened by asymmetric tone/posture ^[1]
Joint hypermobility	Generalised hypotonia → ligamentous laxity
Wide-based gait	Ataxia + spasticity combination

Sign	Pathophysiological Basis
Strabismus	Cranial nerve/cortical visual pathway dysfunction
Tongue thrusting	Oromotor dysfunction
Drooling	Poor oral motor control

Age	Key Features
Neonate / infant (0–12 months)	Feeding difficulty, hypotonia, non-specific developmental delay; may have subtle tongue thrusting; sleep disturbance
Toddler (1–3 years)	Happy demeanour and unprovoked laughter emerge; developmental delay more obvious; seizures begin; ataxic gait when walking achieved; microcephaly evident
Child (3–10 years)	All classic features present; seizures may be most severe in this period; challenging behaviour (hyperactivity, short attention span); sleep problems persist
Adolescent / adult	Seizures may improve; scoliosis worsens; obesity may develop; lifelong severe intellectual disability; communication remains severely limited but nonverbal skills may improve slightly; some develop Parkinsonian features in adulthood

The clinical diagnosis of Angelman syndrome is supported when the following features are present:

Consistent features (100%):

Severe developmental delay / intellectual disability
Movement or balance disorder (ataxia, tremor)
Behavioural uniqueness: happy demeanour, easily provoked laughter, hand-flapping, hypermotor
Speech impairment: no or minimal words, better receptive than expressive language

Frequent features (> 80%):

Postnatal microcephaly (by age 2)
Seizures (onset usually < 3 years)
Characteristic EEG abnormalities

Associated features (20–80%):

Flat occiput, occipital groove
Protruding tongue, wide mouth, widely spaced teeth
Hypopigmentation (deletion patients)
Hyperactive lower limb deep tendon reflexes
Flexed arm posture during walking
Wide-based gait
Increased sensitivity to heat
Sleep disturbance
Attraction to/fascination with water

While the full differential diagnosis and management will be covered in the next response, it is worth noting the key conditions that overlap:

Prader-Willi syndrome: Same chromosomal region, different parental origin of defect — distinguishable clinically and by methylation testing ^[1]^[2]
Rett syndrome: Progressive loss of hand skills + stereotypic hand movements; has speech regression (AS children never develop speech); MECP2 mutation
Pitt-Hopkins syndrome: Severe ID + episodic hyperventilation; TCF4 mutation
Mowat-Wilson syndrome: Severe ID + Hirschsprung disease; ZEB2 mutation
Christianson syndrome (X-linked): Similar to AS; SLC9A6 mutation

High Yield Summary

Angelman Syndrome — Key Points for Exams

UBE3A gene on 15q11-13 is paternally imprinted in the brain → only maternal copy active in neurons → loss of maternal UBE3A = Angelman syndrome ^[1]^[2]^[3]
Most common mechanism: de novo maternal deletion (~70–75%) ^[1]
Incidence: ~1 in 12,000–20,000; M=F; majority de novo ^[1]
Cardinal features: severe developmental delay, (near-)absence of speech, ataxia, epilepsy (80–90%), happy disposition with unprovoked laughter ^[1]
Craniofacial: microcephaly, brachycephaly, macrostomia, protruding tongue, widely-spaced teeth, prominent chin, deep-set eyes ^[1]
Hypopigmentation of skin/hair/eyes occurs in deletion patients due to co-deletion of OCA2 gene ^[1]
Neurological: truncal hypotonia + limb hypertonia ± hyperreflexia + ataxia → characteristic "puppet-like" gait ^[1]
EEG: high-amplitude rhythmic delta activity, characteristic even before clinical seizures ^[4]
Methylation testing confirms AS diagnosis: only paternal (unmethylated) pattern detected ^[2]
Sister disorder: Prader-Willi syndrome (loss of paternal 15q11-13 contribution) — both share hypotonia, developmental delay, and intellectual disability ^[2]
Molecular mechanism determines: phenotype severity, recurrence risk, and genetic counselling ^[1]^[2]
Seizures may worsen with carbamazepine, vigabatrin, phenytoin — avoid these AEDs in AS

Active Recall - Angelman Syndrome (Definition, Epidemiology, Aetiology, Clinical Features)

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 498–500) ^[2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (pp. 859, 863–864) ^[3] Lecture slides: Block C - The malformed child: hereditary syndromes and anomalies.pdf; GC 151. The malformed child hereditary syndromes and anomalies.pdf ^[4] Senior notes: Ryan Ho Neurology.pdf (p. 102 — genetic aetiologies of epilepsy: "Angelman syndrome (up to 90%)")

Differential Diagnosis of Angelman Syndrome

When you encounter a child presenting with the core features of Angelman syndrome — severe developmental delay, (near-)absence of speech, ataxia, epilepsy, and a happy disposition with unprovoked laughter ^[1] — you are really facing a differential of severe intellectual disability (ID) with epilepsy and movement disorder in early childhood. The challenge is that many of these features are non-specific in infancy (hypotonia, feeding difficulty, global developmental delay), and the characteristic behavioural phenotype only crystallises between 1–3 years of age. Therefore, the differential must be considered at two levels:

Before the classic phenotype emerges (infant presenting with hypotonia + developmental delay + seizures): broad differential
After the classic phenotype emerges (toddler/child with severe ID, absent speech, ataxia, epilepsy, happy demeanour): narrower differential of "Angelman-like" conditions

Clinical Reasoning Principle

The differential diagnosis of Angelman syndrome is essentially asking: "What else causes severe intellectual disability + absent/minimal speech + seizures + movement disorder in a young child?" — and then layering on the distinctive behavioural and dysmorphic features to narrow the list. Always think in terms of: (a) other genetic/chromosomal disorders, (b) metabolic disorders, (c) acquired causes (e.g., cerebral palsy from hypoxic-ischaemic encephalopathy).

2. Differential Diagnosis by Category

Because AS and PWS both involve 15q11-13, they are the first pair to differentiate ^[1]^[2]:

Feature	Angelman Syndrome	Prader-Willi Syndrome
Parental origin	Loss of maternal UBE3A	Loss of paternal genes (SNRPN, NDN, etc.)
Tone	↓ Trunk, ↑ limb tone	Profound neonatal hypotonia (improves with age)
Behaviour	Happy, excitable, laughter	Hyperphagia, temper tantrums, OCD ^[1]
Speech	(Near-)absent	Delayed but develops (mild-moderate ID)
Feeding	Difficulty in infancy (oromotor)	Severe feeding difficulty as neonate → hyperphagia in childhood
Growth	Normal stature, microcephaly	Short stature (GH deficiency), obesity ^[1]
Endocrine	Not a feature	Hypothalamic hypogonadism, GH deficiency, hypothyroidism ^[1]
Seizures	80–90%	Uncommon
Methylation	Only paternal (unmethylated) pattern	Only maternal (methylated) pattern ^[2]

Why the confusion can arise: Both share hypotonia and developmental delay in infancy. Methylation-specific testing at 15q11-13 will distinguish them — it is the single first-line test for both conditions ^[2].

These are the most important mimics because they share overlapping features but have different genetic aetiologies. Some are collectively called "Angelman-like" disorders:

Condition	Gene / Mechanism	Key Overlapping Features	Key Distinguishing Features
Rett syndrome	MECP2 (Xq28); X-linked dominant; almost exclusively females	Severe ID, seizures, stereotypic movements, loss of hand skills	Regression (loss of acquired skills, especially purposeful hand use, after 6–18 months); stereotypic hand-wringing/washing; breathing irregularities (hyperventilation/apnoea); progressive course; acquired microcephaly ^[3]
Pitt-Hopkins syndrome	TCF4 (18q21.2); AD, de novo	Severe ID, absent/minimal speech, happy disposition, seizures, microcephaly	Episodic hyperventilation → apnoea (very characteristic); deep-set eyes, wide mouth (similar facies); no ataxia typically; constipation very prominent
Mowat-Wilson syndrome	ZEB2 (2q22); AD, de novo	Severe ID, seizures, happy demeanour, absent speech, microcephaly	Hirschsprung disease (present in ~50%); characteristic facies (widely spaced eyes, broad nasal bridge, pointed chin, uplifted ear lobes); congenital heart defects; genital anomalies
Christianson syndrome	SLC9A6 (Xq26.3); X-linked recessive	Severe ID, absent speech, ataxia, seizures, happy demeanour — most Angelman-like	Affects males only; progressive cerebellar atrophy on MRI; regression may occur; eye movement abnormalities (ophthalmoplegia)
Kleefstra syndrome	EHMT1 (9q34.3); deletion or point mutation	Severe ID, seizures, hypotonia, behavioural problems	Characteristic facies (brachycephaly, midface hypoplasia, synophrys); childhood hypotonia more than limb hypertonia; conotruncal heart defects
FOXG1-related disorder (congenital variant of Rett)	FOXG1 (14q12)	Severe ID, seizures, stereotypic movements, microcephaly	Onset at birth (congenital); hyperkinetic movements; corpus callosum abnormalities on MRI
Fragile X syndrome	FMR1 (Xq27.3); trinucleotide repeat expansion	ID (variable severity), seizures (~20%), behavioural issues	Males predominantly; macro-orchidism (post-pubertal); long face, large ears, prominent jaw; ID usually mild-moderate (not as severe as AS); speech is present though delayed ^[4]^[5]

High Yield: Christianson syndrome is the closest mimic of Angelman syndrome — sometimes called "X-linked Angelman-like syndrome." A boy with an Angelman-like phenotype but negative methylation and UBE3A testing should be tested for SLC9A6 mutations.

Condition	Key Features	Why It Enters the Differential
Down syndrome	Trisomy 21; characteristic facies (upslanting palpebral fissures, epicanthic folds, flat nasal bridge, protruding tongue); epilepsy in ~10%; congenital heart disease (especially AVSD) ^[4]^[5]	Hypotonia + protruding tongue + developmental delay → may be confused in infancy; but facial features and cardiac associations are distinct
1p36 deletion syndrome	Terminal deletion of 1p36; severe ID, seizures, hypotonia, distinctive facies (straight eyebrows, deep-set eyes, midface hypoplasia), cardiomyopathy	Severe ID + seizures + deep-set eyes may overlap; distinguished by cardiac involvement and specific dysmorphism
2q23.1 deletion (MBD5-related)	Severe ID, seizures, absent speech, sleep disturbance, behavioural problems	Very Angelman-like; no specific facial gestalt; requires microarray for diagnosis
Tuberous sclerosis complex (TSC)	TSC1/TSC2; cortical tubers, seizures (infantile spasms), ID, skin findings (ash-leaf spots, shagreen patch, facial angiofibromas) ^[4]	Seizures + ID + hypopigmented skin lesions may overlap with AS deletion patients who have hypopigmentation; distinguished by dermatological findings and characteristic MRI brain

If the motor impairment and abnormal tone have unusual accompanying symptoms, such as unexplained hypoglycaemia, recurrent vomiting, progressively worsening seizures, or there is a family history of unexplained neurological symptoms or infant deaths, one would raise the possibility of an underlying metabolic disorder ^[3]:

Category	Examples	Key Differentiators from AS
Mitochondrial disorders	MELAS, Leigh syndrome, mitochondrial DNA depletion syndromes	Progressive course; multisystem involvement (lactic acidosis, cardiac, hepatic, renal); elevated lactate; MRI shows basal ganglia/brainstem lesions
Organic acidaemias	Glutaric aciduria type 1, propionic acidaemia	Acute metabolic crises; positive newborn screening or urine organic acids; macrocephaly may be present but with acute encephalopathy
Amino acid disorders	Non-ketotic hyperglycinaemia, phenylketonuria (untreated)	NKH: neonatal seizures, apnoea, burst suppression EEG; PKU: progressive ID if untreated, musty odour, eczema; both detectable on NBS
Neuronal ceroid lipofuscinoses (NCL)	CLN1–CLN14	Progressive neurodegeneration (regression), visual loss, myoclonic epilepsy
Mucopolysaccharidoses (MPS)	MPS I (Hurler), MPS II (Hunter), MPS III (Sanfilippo — can present with behavioural issues + seizures + ID)	Coarse facies (progressive), hepatosplenomegaly, skeletal dysplasia; MPS III especially relevant — behavioural disturbance + sleep problems + seizures + progressive ID

Metabolic vs Genetic Cause — Key Distinguishing Principle

The critical differentiating feature is progression vs static: Angelman syndrome causes non-progressive (static) severe ID — the child does not lose acquired skills (unlike Rett syndrome or neurodegenerative conditions). If you see regression (loss of previously acquired milestones), think metabolic/neurodegenerative rather than AS.

Condition	Key Features	Distinction from AS
Cerebral palsy (CP) — especially dyskinetic or ataxic subtypes	History of perinatal insult (HIE, prematurity, kernicterus); motor impairment is predominant; seizures common; abnormal tone with persistence of primitive reflexes ^[3]	Birth history of HIE or prematurity; MRI brain shows periventricular leukomalacia, basal ganglia injury, or other structural lesions; no specific behavioural phenotype (no happy demeanour); dysmorphic features absent
Congenital infections (TORCH)	CMV, toxoplasmosis, rubella	Microcephaly, intracranial calcifications, chorioretinitis, hepatosplenomegaly, sensorineural hearing loss; positive serology
Post-meningitis/encephalitis	History of acute CNS infection	History of febrile illness preceding developmental regression; MRI changes; CSF findings

Condition	Why It Enters the Differential
Autism spectrum disorder (ASD)	Severe cases may present with absent speech, stereotypic behaviours, and intellectual disability; however, the happy disposition with unprovoked laughter is NOT characteristic of ASD — ASD children typically show reduced social reciprocity and restricted affect rather than excessive happy affect ^[6]
22q11.2 deletion syndrome (DiGeorge)	Developmental delay, seizures (from hypocalcaemia), congenital heart defects; distinguished by CATCH-22 features: Cardiac, Abnormal facies, Thymic aplasia, Cleft palate, Hypocalcaemia ^[5]^[7]

Feature	Angelman	Rett	Pitt-Hopkins	Christianson	Prader-Willi	Cerebral Palsy
Sex	M = F	Almost all F	M = F	Males only	M = F	M = F
Regression	No	Yes (6–18 mo)	No	Sometimes	No	No
Speech	Absent/minimal	Lost after regression	Absent/minimal	Absent/minimal	Delayed but present	Variable
Ataxia	Yes (early)	Late/absent	No	Yes	No	Depends on type
Happy demeanour	Hallmark	No (anxious)	Yes (but less prominent)	Yes	No (tantrums, OCD)	No
Hyperventilation	No	Yes (later)	Hallmark	No	No	No
Hirschsprung	No	No	No	No	No	No
Obesity	Usually no	No	No	No	Yes (childhood)	No
Seizures	80–90%	60–80%	50–60%	~90%	Rare	30–50%
Microcephaly	Postnatal	Postnatal (acquired)	Yes	Yes	No	Variable
Hypopigmentation	Deletion only	No	No	No	Yes (deletion)	No

When to Reconsider Angelman Syndrome

Think again if you see any of the following — these features are NOT characteristic of AS and should prompt consideration of alternative diagnoses:

Regression / loss of acquired skills → Rett syndrome, neurodegenerative/metabolic disorder
Normal or near-normal speech development → unlikely AS; consider other causes of ID
Prominent hand stereotypies (hand-wringing/washing) → Rett syndrome
Episodic hyperventilation/apnoea → Pitt-Hopkins syndrome
Hyperphagia and obesity → Prader-Willi syndrome
Congenital structural anomalies (cardiac, renal, GI) → chromosomal disorders (22q11.2, 1p36, trisomy 21)
Progressive course → metabolic or neurodegenerative condition
Macro-orchidism (post-pubertal males) → Fragile X syndrome
Coarse facial features → storage disorders (MPS, mucolipidosis)
Prominent autonomic features → mitochondrial disorders, Rett

When AS is suspected but not yet confirmed, the diagnostic cascade is:

Methylation analysis of 15q11-13 (MS-MLPA or MS-PCR) — detects ~80% of AS cases (deletions + UPD + imprinting defects)
- If abnormal (only paternal/unmethylated pattern): AS confirmed → proceed to mechanism determination (FISH/CMA for deletion → UPD studies → IC analysis)
- If normal: AS still possible (~10–20% have UBE3A point mutations not detected by methylation → proceed to UBE3A gene sequencing
If methylation AND UBE3A sequencing both normal but clinical phenotype is strongly suggestive → consider "Angelman-like" genetic conditions → NGS panel or whole exome sequencing (WES)
If clinical phenotype is less specific → broader workup including chromosomal microarray, metabolic screen (blood/urine amino acids, organic acids, lactate, ammonia), MRI brain, EEG

High Yield Summary — Differential Diagnosis of Angelman Syndrome

Closest mimic: Christianson syndrome (X-linked, SLC9A6) — males with Angelman-like phenotype + progressive cerebellar atrophy on MRI
Sister disorder: Prader-Willi syndrome — same locus (15q11-13), opposite parental origin; distinguished by hyperphagia/obesity, hypogonadism, mild-moderate ID, and speech development
Rett syndrome: Distinguished by regression after 6–18 months, hand-wringing stereotypies, breathing irregularities; almost exclusively females
Pitt-Hopkins: Distinguished by episodic hyperventilation → apnoea
Metabolic/neurodegenerative: Distinguished by progressive course and multisystem involvement
Cerebral palsy: Distinguished by perinatal history, structural MRI lesions, absence of specific behavioural phenotype
Key first-line test: Methylation-specific testing at 15q11-13 — confirms AS and excludes PWS simultaneously ^[2]
If methylation normal, proceed to UBE3A sequencing; if both negative, consider Angelman-like panel / WES

Active Recall - Differential Diagnosis of Angelman Syndrome

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 498–500) ^[2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p. 859) ^[3] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p. 464) ^[4] Senior notes: Ryan Ho Neurology.pdf (p. 102) ^[5] Senior notes: Ryan Ho Cardiology.pdf (p. 185) ^[6] Senior notes: Ryan Ho Psychiatry.pdf (pp. 252–253) ^[7] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p. 875)

Diagnostic Criteria, Diagnostic Algorithm, and Investigations for Angelman Syndrome

1. Consensus Clinical Diagnostic Criteria

Angelman syndrome remains a clinical-genetic diagnosis — there is no single pathognomonic sign, and the diagnosis rests on a combination of clinical features followed by confirmatory molecular testing. The most widely used framework is the revised consensus diagnostic criteria (Williams et al., 2006; updated informally in subsequent expert guidelines).

These must all be present to make a clinical diagnosis:

Feature	Detail / Pathophysiological Basis
1. Severe developmental delay / intellectual disability	Functionally severe (IQ typically < 40); reflects widespread cortical synaptic dysfunction from UBE3A loss ^[1]
2. Movement or balance disorder	Ataxia (cerebellar — UBE3A highly expressed in Purkinje cells) and/or tremulous movement of limbs; gait ataxia is usually the presenting movement feature ^[1]
3. Behavioural uniqueness	Happy disposition with frequent, unprovoked laughter and smiling; easily excited; hypermotoric; hyperactive; hand-flapping — reflects altered mesolimbic dopaminergic/serotonergic signalling ^[1]
4. Speech impairment	No or minimal use of words; receptive language better than expressive; nonverbal communication relatively preserved ^[1]

Feature	Notes
Postnatal microcephaly	Usually by age 2 years; absolute or relative (head circumference deceleration crossing centiles) ^[1]
Seizures	Onset typically < 3 years; multiple seizure types (myoclonic, atypical absence, GTC, atonic); up to 80–90% of patients ^[1]^[4]
Characteristic EEG abnormalities	High-amplitude rhythmic 2–3 Hz delta (frontal); intermittent rhythmic 4–6 Hz theta (posterior); facilitated by eye closure; may precede clinical seizures ^[4]

Feature	Notes
Flat occiput, occipital groove	Part of craniofacial gestalt
Protruding tongue, wide mouth, widely-spaced teeth	Oromotor hypotonia + facial dysmorphism ^[1]
Prominent chin (prognathia)	More apparent with age ^[1]
Hypopigmentation of skin, hair, eyes	Only in deletion patients (co-deletion of OCA2) ^[1]
Hyperactive lower limb deep tendon reflexes	Upper motor neuron pattern
Flexed arm posture during ambulation	"Arms-up" posture due to limb hypertonia + ataxia
Wide-based gait	Cerebellar ataxia
Increased sensitivity to heat	Autonomic dysregulation
Sleep disturbance	Reduced total sleep, frequent awakenings; ↓melatonin ^[1]
Attraction to / fascination with water	Classic behavioural quirk

When to Suspect Angelman Syndrome Clinically

A child aged 1–3 years with all four consistent features (severe GDD, no speech, ataxia, happy demeanour) should undergo molecular testing for AS as a priority. Do not wait for every associated feature — the consistent tetrad is sufficient to trigger testing. Early suspicion is important because it guides seizure management (avoid carbamazepine/phenytoin) and facilitates family genetic counselling.

Clinical features alone are insufficient for a definitive diagnosis of Angelman syndrome. Molecular confirmation is required ^[1]^[2]. The molecular testing strategy is a stepwise cascade designed to identify the specific mechanism (which determines prognosis and recurrence risk):

Test	What It Detects	Sensitivity	Result in AS
Step 1: Methylation analysis (MS-MLPA or MS-PCR)	Methylation status at 15q11-13 ICR	Detects ~80% of AS cases (all deletions, UPD, imprinting defects)	Only the paternal (unmethylated) pattern is present — the maternal (methylated) pattern is absent ^[2]
Step 2 (if methylation abnormal): Mechanism determination
— FISH or chromosomal microarray (CMA)	Deletion at 15q11-13	Detects the ~70–75% with deletion	Maternal deletion identified; CMA also defines deletion size (Class I vs II)
— Microsatellite / SNP analysis for UPD	Paternal UPD	Detects the ~2–5% with UPD	Two paternal chromosomes 15, no maternal
— IC analysis	Imprinting centre defect	Detects the ~3–5% with IC defects	Abnormal methylation without deletion or UPD; may have microdeletion of IC
Step 3 (if methylation NORMAL): UBE3A sequencing	Point mutation in UBE3A gene	Detects the ~10–20% with UBE3A mutations	Pathogenic missense, nonsense, frameshift, or splice-site variant in UBE3A
Step 4 (if all above negative): Consider AS-like panel / WES	Other genetic causes of Angelman-like phenotype	Variable	Mutations in SLC9A6, TCF4, MECP2, FOXG1, ZEB2, EHMT1, MBD5 etc.

Why Methylation Testing Is First-Line

Methylation-specific testing is the single most useful first-line investigation because:

It detects ~80% of all AS cases in one assay (deletions + UPD + imprinting defects)
It simultaneously excludes Prader-Willi syndrome (which shows only maternal/methylated pattern) ^[2]
It is non-invasive (blood sample), relatively rapid (days), and widely available
A normal result does NOT exclude AS — must proceed to UBE3A sequencing (Step 3) for the remaining ~10–20%

4. Investigation Modalities — Detailed Interpretation

4.1 Genetic / Molecular Investigations

Principle: Uses methylation-sensitive restriction enzymes combined with MLPA probes targeting the 15q11-13 ICR. Differentially methylated CpG sites on maternal vs paternal alleles produce distinct fragment patterns.
What it tells you:
- Normal: Both maternal (methylated) and paternal (unmethylated) bands present → two normally imprinted alleles
- AS pattern: Only paternal (unmethylated) band → maternal allele absent or silenced ^[2]
- PWS pattern: Only maternal (methylated) band
Advantage over MS-PCR: MS-MLPA simultaneously detects copy number (i.e., deletions/duplications) AND methylation status in one assay
Limitation: Cannot distinguish UPD from imprinting defects (both show abnormal methylation without deletion)

Principle: Fluorescently labelled DNA probes specific to the 15q11-13 region hybridise to metaphase chromosomes; absence of signal on one homologue = deletion
What it tells you: Presence or absence of the 15q11-13 segment; does NOT tell you which parent's allele is deleted (need methylation context)
Largely superseded by CMA but still used in some centres

Principle: Genome-wide high-resolution detection of copy number variants (deletions and duplications)
What it tells you:
- Confirms deletion at 15q11-13
- Defines deletion breakpoints (Class I [BP1–BP3, ~6 Mb] vs Class II [BP2–BP3, ~5 Mb]) — important because Class I deletions are larger and encompass more genes (including NIPA1, NIPA2, CYFIP1, TUBGCP5) → may contribute to more severe phenotype
- May also detect other chromosomal abnormalities if AS is not the diagnosis
Limitation: Cannot detect UPD, imprinting defects, or point mutations

Principle: Genotype informative microsatellite markers (or genome-wide SNPs) on chromosome 15 in the proband and both parents; if the child has two copies of paternal chromosome 15 markers and none of maternal → paternal UPD
When to do it: After methylation analysis shows abnormal pattern BUT CMA shows no deletion

Principle: Targeted sequencing or deletion analysis of the bipartite IC (AS-SRO and PWS-SRO) within 15q11-13
When to do it: After deletion and UPD are excluded but methylation is abnormal
Clinical significance: IC deletions may be inherited from the mother (who is phenotypically normal because she inherited the IC deletion from her father) → up to 50% recurrence risk — critical for counselling

Principle: Direct sequencing of all coding exons and splice sites of the UBE3A gene to identify point mutations (missense, nonsense, frameshift, splice-site)
When to do it: When methylation analysis is NORMAL — these patients have intact imprinting but a defective UBE3A gene on the maternal allele ^[1]^[2]
What it tells you: Pathogenic variant identified → UBE3A mutation AS (Class III)
Recurrence risk: If the mother carries the same mutation → up to 50%; if the mutation is de novo in the child → low recurrence

When to do it: When methylation, CMA, UPD, IC analysis, AND UBE3A sequencing are all negative but clinical phenotype is highly suggestive → look for "Angelman-like" disorders
Genes typically included: SLC9A6 (Christianson), TCF4 (Pitt-Hopkins), MECP2 (Rett), FOXG1, ZEB2 (Mowat-Wilson), EHMT1 (Kleefstra), MBD5, CDKL5, MEF2C

EEG Pattern	Description	Clinical Significance
High-amplitude rhythmic delta activity (2–3 Hz)	Runs of high-voltage slow waves, most prominent over frontal regions	Highly characteristic of AS; may be present even before clinical seizures manifest; seen in > 80% of patients ^[4]
Intermittent rhythmic theta activity (4–6 Hz)	Posterior predominance	Often intermixed with delta activity
Epileptiform discharges facilitated by eye closure	Spike-wave complexes or polyspike discharges appearing within seconds of eye closure	Relatively specific to AS among causes of severe ID with epilepsy
Notched delta pattern	"Notching" within the slow waves	Described as suggestive of AS

High Yield: The EEG in AS can be a diagnostic clue even in infancy, before the behavioural phenotype is evident. A child with developmental delay + seizures + characteristic EEG should prompt methylation testing even if the behavioural features are not yet classic.

Interpretation pitfalls:

The EEG pattern evolves with age — it may be less distinctive in the first 6 months or in adolescence/adulthood
Not 100% specific — some other severe epileptic encephalopathies can produce similar patterns
EEG does NOT confirm the diagnosis alone — it supports it and guides further genetic testing

Finding	Expected in AS	Significance
Structural abnormalities	Usually normal or near-normal	AS is a disorder of synaptic function, not gross brain structure
Mild cerebral atrophy / delayed myelination	May be seen in some patients	Non-specific; does not confirm diagnosis
Cerebellar abnormalities	Occasionally mild vermian atrophy in older patients	Consistent with cerebellar dysfunction (ataxia)
Role	Primarily to exclude structural causes (cortical malformations, HIE changes, tumours, metabolic white matter disease)	A normal MRI in a child with severe ID + seizures + ataxia supports a genetic aetiology like AS over an acquired cause like cerebral palsy

MRI Brain in Angelman Syndrome

A common mistake is to expect dramatic MRI findings in AS. The MRI is usually normal or shows only subtle non-specific changes. If the MRI shows significant structural pathology (e.g., periventricular leukomalacia, basal ganglia signal abnormality, severe cerebellar atrophy), you should reconsider the diagnosis — think cerebral palsy, metabolic disorder, or Christianson syndrome (which shows progressive cerebellar atrophy) instead.

These are not diagnostic of AS but are important to exclude metabolic disorders that can present similarly (especially if molecular testing is negative or pending):

Investigation	What It Excludes	Key Findings Suggesting Metabolic Aetiology
Blood gas + lactate	Mitochondrial disorders, organic acidaemias	High anion gap metabolic acidosis, hyperlactacidaemia ^[5]
Plasma amino acids	Aminoacidopathies (e.g., PKU, NKH)	Elevated specific amino acids (e.g., phenylalanine in PKU, glycine in NKH)
Urine organic acids	Organic acidaemias (e.g., glutaric aciduria)	Characteristic organic acid patterns
Blood ammonia	Urea cycle defects	Hyperammonaemia
Plasma acylcarnitine profile	Fatty acid oxidation defects	Abnormal acylcarnitine species
Blood glucose	Glycogen storage diseases, congenital hyperinsulinism	Hypoglycaemia
Urine mucopolysaccharides / oligosaccharides	MPS, oligosaccharidoses	Elevated MPS or oligosaccharide excretion
Transferrin isoelectric focusing	Congenital disorders of glycosylation (CDG)	Abnormal transferrin pattern

If the motor impairment and abnormal tone have unusual accompanying symptoms, such as unexplained hypoglycaemia, recurrent vomiting, progressively worsening seizures, or there is a family history of unexplained neurological symptoms or infant deaths, one would raise the possibility of an underlying metabolic disorder ^[3]^[5]

Investigation	Purpose	Expected Findings in AS
Developmental assessment (Bayley, Griffiths)	Quantify developmental delay	Severe global delay; may help track progress with intervention
Sleep study (polysomnography)	Evaluate sleep architecture	Reduced total sleep time, frequent awakenings, ↓REM sleep
Scoliosis screening (spinal radiograph)	Monitor for scoliosis	May show thoracolumbar scoliosis, especially in older children/adolescents
Ophthalmology assessment	Strabismus screening	May detect strabismus, refractive errors, or ocular albinism (deletion patients)
Swallowing assessment	Evaluate feeding safety	Oromotor dysfunction, risk of aspiration

Scenario: A 2-year-old boy presents with severe global developmental delay, no words, ataxic wide-based gait, frequent unprovoked laughter, and onset of myoclonic seizures at 18 months. EEG shows high-amplitude 2–3 Hz frontal delta activity. Mum notes he is fairer than his older siblings.

Clinical impression: Consistent features all present → high suspicion for Angelman syndrome
Step 1 — Methylation analysis (MS-MLPA): Result → only paternal (unmethylated) pattern detected → AS confirmed molecularly
Step 2 — CMA: Result → 5.1 Mb deletion at 15q11.2-q13.1 (Class II, BP2–BP3) → Deletion AS confirmed
- Hypopigmentation explained: OCA2 gene within the deleted region → reduced melanin → fairer than siblings
- Seizure severity explained: GABRB3/GABRG3 (GABA-A receptor subunit genes) within the deletion → lowered seizure threshold
Parental testing: Parents both have normal karyotype and no 15q rearrangement → de novo deletion → recurrence risk < 1%
Genetic counselling: Low recurrence; offer prenatal methylation testing in future pregnancies if family desires

Principle	Explanation
Clinical suspicion first	The four consistent features (severe GDD, no speech, ataxia, happy demeanour) trigger testing
Methylation analysis is the gateway test	Detects ~80% of cases; simultaneously excludes PWS ^[2]
Mechanism determination matters	Dictates recurrence risk (< 1% for deletion/UPD vs up to 50% for inherited UBE3A mutation or IC deletion)
Normal methylation ≠ no AS	~10–20% have UBE3A point mutations → must proceed to gene sequencing
EEG supports but does not confirm	Characteristic pattern is highly suggestive but not pathognomonic
MRI is usually normal	Main role is to exclude structural/metabolic causes
Metabolic screen if doubt	Especially if progressive course, regression, or systemic features present ^[3]^[5]

High Yield Summary — Diagnosis of Angelman Syndrome

Consensus clinical criteria: 4 consistent features (all must be present) — severe GDD, no speech, ataxia/tremor, happy demeanour with unprovoked laughter ^[1]
Frequent features (> 80%): postnatal microcephaly, seizures (onset < 3 years), characteristic EEG ^[1]^[4]
First-line test: Methylation analysis (MS-MLPA/MS-PCR) — detects ~80% of cases; shows only paternal (unmethylated) pattern in AS ^[2]
If methylation abnormal → determine mechanism: CMA (deletion) → UPD studies → IC analysis
If methylation normal → UBE3A sequencing (detects ~10–20% with point mutations) ^[1]
If all negative → NGS panel / WES for Angelman-like disorders
EEG: high-amplitude 2–3 Hz frontal delta, theta bursts, eye-closure-facilitated epileptiform discharges ^[4]
MRI brain: usually normal; role is to exclude structural/metabolic pathology
Mechanism determines recurrence risk: deletion/UPD < 1%; inherited UBE3A mutation or IC deletion up to 50%
Metabolic screen indicated if progressive course, regression, or atypical systemic features ^[3]^[5]

Active Recall - Diagnostic Criteria, Algorithm, and Investigations for Angelman Syndrome

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 498–500) ^[2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p. 859) ^[3] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p. 464) ^[4] Senior notes: Ryan Ho Neurology.pdf (p. 102) ^[5] Lecture slides: Chemical Pathology Seminar_Inherited metabolic disease 2025.pdf (p. 11)

Management Algorithm and Treatment of Angelman Syndrome

There is no cure for Angelman syndrome. UBE3A gene function cannot currently be restored, so management is entirely symptomatic, supportive, and preventive — aimed at maximising developmental potential, controlling seizures, managing behavioural difficulties, and supporting the family. The approach is multidisciplinary and lifelong ^[1].

The key management pillars are:

Pillar	Rationale
1. Seizure management	The most medically urgent aspect; seizures affect up to 80–90% and can be treatment-resistant ^[1]^[4]
2. Developmental and behavioural therapies	Maximise communication, motor function, adaptive skills, and quality of life
3. Sleep management	Sleep disturbance affects ~80%; impacts child and family wellbeing
4. Musculoskeletal surveillance	Scoliosis, joint contractures from spasticity
5. Nutritional and feeding support	Oromotor dysfunction, drooling, aspiration risk
6. Family-centred care and genetic counselling	Emotional support, recurrence risk counselling, transition planning
7. Emerging / investigational therapies	Gene therapy, antisense oligonucleotides — not yet standard of care

Family-Centred Care Is Central

Angelman syndrome is a lifelong condition diagnosed in early childhood. Every management decision should be made with the family, using language they understand, acknowledging the emotional impact of the diagnosis, and connecting them with support networks (e.g., Angelman Syndrome Foundation, local parent groups in Hong Kong). In the paediatric setting, parental consent is required for all interventions, and as the child grows, assent should be sought where developmentally appropriate — though most AS patients will lack capacity for independent decision-making.

3. Detailed Treatment Modalities

3.1 Seizure Management — The Most Critical Aspect

Epilepsy occurs in up to 80–90% of patients ^[1]^[4]
Onset typically 1–3 years
Multiple seizure types coexist: myoclonic, atypical absence, generalised tonic-clonic (GTC), atonic
Seizures can be very frequent (dozens per day) and drug-resistant in many patients
The mechanism involves both UBE3A loss (neuronal hyperexcitability from impaired protein degradation → synaptic dysfunction) and, in deletion patients, co-deletion of GABA-A receptor subunit genes (GABRB3, GABRG3) → further lowered seizure threshold
Certain AEDs can paradoxically worsen seizures — this is the single most important management fact for exams

Drug	Mechanism	Why It Works in AS	Paediatric Dosing	Side Effects
Sodium valproate (VPA)	Broad-spectrum AED: ↑GABA, blocks Na+ and T-type Ca2+ channels	Effective against multiple seizure types (myoclonic, absence, GTC) — ideal for AS's mixed seizure profile	Start 10–15 mg/kg/day in 2–3 divided doses; titrate to 20–40 mg/kg/day; target level 50–100 µg/mL	Hepatotoxicity (monitor LFTs — higher risk in < 2 years, mitochondrial disease), weight gain, tremor, thrombocytopenia, teratogenicity (counsel adolescent females)
Levetiracetam (LEV)	Binds SV2A (synaptic vesicle protein 2A) → modulates neurotransmitter release	Broad-spectrum; good tolerability in children; available as oral solution	Start 10 mg/kg/day in 2 divided doses; titrate to 20–60 mg/kg/day	Behavioural side effects (irritability, aggression — problematic in AS where behaviour is already challenging), somnolence

High Yield: Valproate is generally considered the first-choice AED for Angelman syndrome because of its broad-spectrum efficacy against all seizure types seen in AS. However, in children under 2 years, the risk of valproate-induced hepatotoxicity is higher → levetiracetam may be preferred initially.

Drug	Mechanism	Indication in AS	Paediatric Dosing	Side Effects
Clobazam	Benzodiazepine (enhances GABA-A receptor function at α2 subunit — less sedation than other BZDs)	Effective add-on for myoclonic and GTC seizures; may be better tolerated than clonazepam	0.1–0.5 mg/kg/day in 1–2 doses	Sedation, tolerance (efficacy may wane), drooling (problematic in AS)
Clonazepam	Benzodiazepine (GABA-A agonist)	Myoclonic seizures, atypical absences	0.01–0.05 mg/kg/day in 2–3 doses	Sedation, hypersalivation, ataxia (may worsen existing AS ataxia)
Ethosuximide	T-type Ca2+ channel blocker in thalamic neurons	Specifically for atypical absence seizures	10–20 mg/kg/day; max 40 mg/kg/day	GI upset, headache, drowsiness; NOT effective for GTC (so usually add-on, not monotherapy)

Intervention	Mechanism / Rationale	Notes
Topiramate	Multiple mechanisms (Na+ channel, GABA-A, AMPA/kainate, carbonic anhydrase)	Broad-spectrum; may also help with weight management; risk of cognitive side effects (language/word-finding — less relevant in AS where speech is already absent), metabolic acidosis, nephrolithiasis
Ketogenic diet	High-fat, low-carbohydrate diet → ketosis → anticonvulsant effect (shifts brain energy substrate from glucose to ketone bodies; may enhance GABA synthesis and reduce neuronal excitability)	Requires dedicated dietetic supervision; may be challenging given feeding difficulties in AS; evidence supports efficacy in drug-resistant epilepsy; used in specialised paediatric centres in HK
Vagus nerve stimulation (VNS)	Intermittent electrical stimulation of left vagus nerve via implanted pulse generator → modulates brainstem nuclei involved in seizure propagation	Reserved for drug-resistant epilepsy; palliative (reduces seizure frequency/severity rather than eliminating seizures); surgical implantation required

Drugs That WORSEN Seizures in Angelman Syndrome

The following AEDs can paradoxically exacerbate seizures in AS — particularly myoclonic and absence seizure types. They must be avoided:

Drug	Why It Worsens AS Seizures
Carbamazepine (CBZ)	Na+ channel blocker effective for focal seizures but aggravates generalised seizure types (myoclonic, absence) by enhancing thalamocortical synchronisation; specifically known to worsen AS epilepsy ^[1]
Phenytoin (PHT)	Same mechanism as CBZ — Na+ channel blockade; can worsen myoclonic and absence seizures
Vigabatrin (VGB)	Irreversible GABA transaminase inhibitor; paradoxically worsens myoclonic seizures (mechanism not fully understood — may relate to excessive GABAergic inhibition in specific circuits causing rebound excitability)
Tiagabine	GABA reuptake inhibitor; same issue as vigabatrin — can precipitate non-convulsive status epilepticus
Gabapentin / Pregabalin	Ca2+ channel α2δ ligands; may worsen myoclonic seizures

Clinical pearl: If a child with undiagnosed AS is started on carbamazepine for presumed focal epilepsy and seizures worsen dramatically → think about AS and request methylation testing!

Scenario	Management
Acute prolonged seizure / status epilepticus	Standard paediatric protocol: buccal midazolam (0.5 mg/kg, max 10 mg) or rectal diazepam (0.5 mg/kg) → IV lorazepam (0.1 mg/kg) → IV phenobarbital (20 mg/kg) or IV levetiracetam (40 mg/kg); AVOID IV phenytoin
Seizure action plan	Every AS family should have a written plan; parents trained in buccal midazolam administration; emergency contact details
Fever management	Low threshold for antipyretics (paracetamol 15 mg/kg/dose q4–6h) as febrile seizures are very common in AS

3.2 Developmental and Behavioural Therapies

Approach	Rationale
Augmentative and Alternative Communication (AAC)	Since speech is absent or minimal ^[1], AAC devices are the primary communication strategy: picture exchange communication systems (PECS), communication boards, eye-gaze technology, tablet-based speech apps
Sign language / gesture-based communication	Many AS children can learn simple signs or gestures; receptive language is better than expressive — they understand more than they can say
Oral motor therapy	Addresses tongue thrusting, drooling, and feeding difficulties

Why AAC works: AS children have relatively preserved receptive language and nonverbal cognition — they can learn to associate pictures/symbols with meanings even though they cannot articulate words. Early introduction of AAC (before age 2–3) improves long-term communicative outcomes.

Therapy	Goals	Specific Approaches
Physiotherapy	Improve mobility, balance, and gross motor skills; manage spasticity; prevent contractures	Gait training (often with supportive aids), hydrotherapy (water-based therapy — many AS children love water), stretching programmes, ankle-foot orthoses (AFOs) for equinovarus deformity from lower limb spasticity
Occupational therapy	Improve fine motor skills, self-care (feeding, dressing), sensory integration	Adaptive equipment, hand function exercises, sensory diet for sensory-seeking behaviours

Issue	Approach
Hyperactivity / short attention span	Structured environment, consistent routines, positive reinforcement; no role for stimulant medications (e.g., methylphenidate) as these may lower seizure threshold
Self-stimulatory / stereotypic behaviours	Redirect rather than suppress; ensure environmental enrichment
Water fascination	Supervise near water at all times — drowning risk

Step	Intervention	Mechanism / Rationale
1. Sleep hygiene	Consistent bedtime routine, dark room, avoid screens, calming activities before bed	Non-pharmacological first-line; addresses behavioural component of sleep disturbance
2. Melatonin	Exogenous melatonin (0.5–5 mg, given 30–60 min before target bedtime)	AS patients have documented reduced endogenous melatonin secretion → exogenous supplementation restores circadian signalling; improves sleep onset latency and total sleep time; well-tolerated with minimal side effects; first-line pharmacological intervention for AS sleep problems
3. Adjunct sedatives	Trazodone, clonidine (rarely needed)	Second-line if melatonin insufficient; use with caution — sedation may worsen daytime hypotonia or mask seizure activity

Why melatonin is particularly effective in AS: Studies have shown that AS patients have abnormal melatonin circadian profiles — likely related to UBE3A's role in regulating the molecular clock. Exogenous melatonin directly compensates for this deficit. It is safe in children, available as liquid formulations suitable for paediatric use, and has no significant drug interactions with AEDs.

Problem	Management
Scoliosis ^[1]	Screen with clinical examination (Adam's forward bend test) at every visit; spinal radiograph if clinical concern; mild curves → physiotherapy and bracing; progressive curves > 40–50° → consider surgical correction (spinal fusion) — anaesthetic risk management essential given epilepsy and hypotonia
Lower limb spasticity	Stretching, AFOs, botulinum toxin injections (for focal spasticity, e.g., ankle plantarflexors); oral baclofen or diazepam rarely used (sedation, worsened hypotonia)
Joint contractures	Preventive stretching programme; serial casting if needed
Osteoporosis	Higher risk due to AED use (valproate affects bone metabolism), reduced mobility, and possibly low vitamin D; ensure adequate calcium and vitamin D supplementation; weight-bearing activity where possible

Issue	Management
Feeding difficulty (infancy) ^[1]	Assess by speech therapist / feeding specialist; positioning optimisation; thickened feeds if aspiration risk; rarely may need nasogastric tube (short-term) or gastrostomy (long-term if severe oromotor dysfunction)
Drooling	Anticholinergics (glycopyrrolate 20–40 µg/kg/dose TDS — reduces salivary secretion); botulinum toxin to salivary glands; rarely submandibular duct ligation
Constipation	Very common (hypotonia of GI smooth muscle); dietary fibre, adequate fluids, lactulose or macrogol (polyethylene glycol) as osmotic laxatives
Obesity risk (adolescence/adulthood)	Monitor BMI; dietary guidance; physical activity encouragement

Glycopyrrolate for Drooling — Paediatric Dosing

Glycopyrrolate (glycopyrronium) is a quaternary ammonium anticholinergic that does not cross the blood-brain barrier (unlike atropine) — so it reduces salivary secretion without causing central sedation or lowering seizure threshold. This makes it the preferred agent for drooling in children with epilepsy. Dose: 20–40 µg/kg/dose, given 3 times daily, oral solution available.

Molecular Mechanism	Recurrence Risk	Counselling Points
De novo deletion	< 1%	Reassuring for future pregnancies; offer prenatal methylation testing if family desires
Paternal UPD	< 1%	Low risk; associated with advanced maternal age (trisomy rescue mechanism)
Imprinting defect — epimutation	< 1%	Stochastic event
Imprinting defect — IC deletion	Up to 50%	If the IC deletion is inherited from the mother (who is phenotypically normal because she inherited it from her father), each pregnancy has 50% chance of AS
UBE3A point mutation	Up to 50%	If the mother carries the same mutation; critical to test the mother
Unknown mechanism	Empirical ~10%	Uncertainty; discuss limitations of current testing

Practical counselling: Always determine the molecular mechanism before counselling the family about recurrence risk. A blanket "low risk" statement is incorrect for inherited UBE3A mutations or IC deletions. Offer carrier testing for the mother in all UBE3A mutation and IC deletion cases.

Prenatal testing options (for at-risk pregnancies):

Chorionic villus sampling (CVS) at 11–13 weeks or amniocentesis at 15–18 weeks → methylation analysis + mechanism-specific testing
Pre-implantation genetic testing (PGT) via IVF — available for families with known pathogenic variant

Age	Assessments
0–2 years	Confirm molecular diagnosis; initiate early intervention (PT, OT, SLT); baseline EEG; feeding assessment; genetic counselling for parents
2–5 years	Seizure management optimisation; developmental assessment; introduce AAC; ophthalmology review (strabismus); sleep assessment → melatonin if needed
5–12 years	Annual scoliosis screening; ongoing AED management; school support (special education); dental care (widely spaced teeth, bruxism); bone health assessment
12–18 years	Puberty management (menstrual management in females if needed); scoliosis surveillance intensified; transition planning; obesity prevention
> 18 years	Transition to adult services; ongoing seizure management (seizures often improve in adulthood); guardianship / legal capacity arrangements; respite care; lifelong community support

Therapy	Mechanism	Status (2025)
Antisense oligonucleotides (ASOs) targeting UBE3A-ATS	In neurons, the paternal UBE3A allele is silenced by a long antisense transcript (UBE3A-ATS). ASOs degrade this antisense transcript → unsilence the paternal UBE3A copy → restore UBE3A protein in neurons	Phase 1/2 clinical trials (e.g., GTX-102 by Ultragenyx); intrathecal administration; promising preclinical data in mouse models; clinical trials paused/restarted due to safety signals (lower limb weakness); active area of research
Gene replacement therapy (AAV-mediated UBE3A delivery)	Adeno-associated virus vector carrying functional UBE3A gene → delivered to CNS → express UBE3A in neurons	Preclinical; challenges include delivery to sufficient brain regions, durability of expression, and avoiding immune response
Small molecule approaches	Topoisomerase inhibitors (e.g., topotecan) can unsilence paternal UBE3A in preclinical models by disrupting UBE3A-ATS transcription	Very early preclinical; toxicity concerns limit clinical translation
Dietary supplement (minocycline)	Matrix metalloproteinase inhibitor; some evidence of benefit on EEG and developmental parameters in small studies	No strong evidence; not recommended as standard care

ASO Therapy — The Future of AS Treatment?

The concept is elegant: since the paternal UBE3A gene is structurally intact but epigenetically silenced by the antisense transcript, you don't need to replace the gene — you just need to remove the silencer. ASOs that degrade UBE3A-ATS can "wake up" the dormant paternal copy and restore functional UBE3A protein. This is potentially a disease-modifying therapy rather than merely symptomatic. However, timing matters — earlier intervention (before irreversible synaptic changes) may be more effective, creating urgency for early diagnosis.

Intervention	Contraindications / Cautions
Valproate	Avoid in children < 2 years if possible (hepatotoxicity risk); avoid in known mitochondrial disease (POLG mutations → fatal hepatotoxicity); counsel re: teratogenicity in adolescent females
Carbamazepine, phenytoin, vigabatrin, tiagabine, gabapentin	CONTRAINDICATED in AS — worsen myoclonic and absence seizures
Benzodiazepines	Caution: sedation, paradoxical excitation in some children, tolerance; may worsen hypotonia; drooling with clobazam/clonazepam
Stimulant medications (methylphenidate)	Not indicated — may lower seizure threshold; hyperactivity in AS is not ADHD
Ketogenic diet	Contraindicated in fatty acid oxidation defects, pyruvate carboxylase deficiency, carnitine deficiency; monitor growth carefully in growing children
Botulinum toxin	Local spread may worsen generalised hypotonia — use cautiously, only in focal spasticity

High Yield Summary — Management of Angelman Syndrome

No cure exists — management is multidisciplinary, symptomatic, and supportive
Seizure management is the most critical aspect:
- First-line: valproate (broad-spectrum) or levetiracetam (if < 2 years or valproate contraindicated)
- Add-on: clobazam, clonazepam, ethosuximide
- Refractory: topiramate, ketogenic diet, vagus nerve stimulation
- AVOID carbamazepine, phenytoin, vigabatrin, tiagabine, gabapentin — all worsen myoclonic/absence seizures ^[1]
Communication: Augmentative and Alternative Communication (AAC) is essential; PECS, communication boards, eye-gaze technology
Sleep: Melatonin is first-line pharmacotherapy (AS patients have ↓endogenous melatonin)
Scoliosis requires regular screening; bracing or surgery for progressive curves ^[1]
Feeding: Oromotor assessment; glycopyrrolate for drooling; constipation management
Genetic counselling: Recurrence risk varies by mechanism — < 1% for de novo deletion/UPD vs up to 50% for inherited UBE3A mutation or IC deletion
Emerging therapy: ASOs targeting UBE3A-ATS to unsilence paternal UBE3A — potentially disease-modifying; in clinical trials
Transition planning to adult services is critical — lifelong condition with ongoing care needs

Active Recall - Management of Angelman Syndrome

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 498–500) ^[2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p. 859) ^[4] Senior notes: Ryan Ho Neurology.pdf (p. 102)

Complications of Angelman Syndrome

Angelman syndrome is a lifelong condition, and its complications arise from two overlapping sources:

Direct consequences of UBE3A deficiency — the primary neurological dysfunction (seizures, movement disorder, intellectual disability) and its downstream effects on every body system
Secondary consequences of the clinical phenotype — e.g., immobility → scoliosis → respiratory compromise; oromotor dysfunction → aspiration; AED use → bone demineralisation

Complications evolve across the lifespan. In childhood, seizures and feeding difficulties dominate. In adolescence and adulthood, musculoskeletal problems (scoliosis, contractures), behavioural challenges, and comorbidities of long-term AED use become increasingly important. Understanding complications from first principles helps you anticipate, screen for, and prevent them.

2. Neurological Complications

Complication	Pathophysiological Basis	Clinical Details
Drug-resistant epilepsy	Loss of UBE3A → neuronal hyperexcitability; co-deletion of GABA-A receptor subunit genes (GABRB3, GABRG3) in large-deletion patients → profoundly lowered seizure threshold	Epilepsy occurs in up to 80–90% ^[1]^[4]; multiple seizure types coexist; ~50% remain difficult to control despite optimised AED therapy; seizures are typically most severe in childhood (3–10 years) and often improve (but rarely resolve) in adolescence/adulthood
Status epilepticus	Sustained neuronal hyperexcitability; may be triggered by febrile illness, AED non-compliance, or inappropriate AED choice	Higher risk than general epilepsy population; non-convulsive status epilepticus (prolonged atypical absences) may be under-recognised — child appears "zoned out" rather than convulsing; EEG confirmation needed
Seizure-related injuries	Atonic seizures (sudden drop attacks) or myoclonic seizures during standing/walking → falls	Falls with facial/dental injuries; higher risk because of pre-existing ataxia + spasticity; protective helmets may be needed
Sudden unexpected death in epilepsy (SUDEP)	Poorly understood; likely involves seizure-mediated cardiac arrhythmia and/or central apnoea	Risk is elevated in any patient with drug-resistant epilepsy; risk-reduction strategies include optimising seizure control, nocturnal supervision, and seizure monitoring devices

Non-Convulsive Status Epilepticus — Easily Missed

In a child with AS who appears more drowsy, less responsive, or "not themselves" for hours to days, always consider non-convulsive status epilepticus. Because AS children already have minimal speech and limited interaction, subtle seizure activity can be masked by the baseline neurological picture. A prolonged EEG is the only way to confirm or exclude this. Delayed recognition leads to prolonged brain exposure to ictal activity, potentially worsening cognitive function further.

AED	Complication	Mechanism
Valproate	Hepatotoxicity (especially < 2 years), weight gain, tremor, thrombocytopenia, teratogenicity, hyperammonaemia, pancreatitis (rare)	Idiosyncratic mitochondrial toxicity (hepatic); inhibition of fatty acid β-oxidation; dose-related bone marrow suppression
Valproate	Bone demineralisation / osteoporosis	VPA induces hepatic enzyme activity → ↑vitamin D catabolism → ↓calcium absorption; also direct osteoclast activation
Levetiracetam	Behavioural side effects (irritability, aggression)	Mechanism poorly understood; may relate to SV2A modulation affecting mood circuits; particularly problematic in AS where behavioural management is already challenging
Benzodiazepines (clobazam, clonazepam)	Tolerance (reduced efficacy over time), paradoxical excitation, excessive sedation, worsened drooling/hypersalivation	GABA-A receptor desensitisation with chronic use
Topiramate	Metabolic acidosis, nephrolithiasis, weight loss (may be beneficial or harmful depending on nutritional status), cognitive side effects	Carbonic anhydrase inhibition → renal bicarbonate wasting; ↓urinary citrate → calcium phosphate stones
Ketogenic diet	Hyperlipidaemia, nephrolithiasis, growth deceleration, constipation, metabolic acidosis	High-fat diet → ↑serum lipids; chronic ketosis → acid load; reduced dietary variety → micronutrient deficiencies

High Yield: Every AS patient on long-term AEDs (especially valproate) should have regular bone health monitoring — DEXA scan where feasible, and routine calcium + vitamin D supplementation. Osteoporosis risk is compounded by reduced weight-bearing activity due to motor disability.

Complication	Pathophysiological Basis	Clinical Management
Scoliosis	Truncal hypotonia → poor paraspinal muscle support → progressive spinal curvature; asymmetric tone (limb hypertonia vs truncal hypotonia) creates unbalanced forces on the growing spine; prevalence increases with age — up to 50–70% of AS patients develop clinically significant scoliosis by adolescence ^[1]	Screen at every clinic visit (Adam's forward bend test); spinal radiograph if clinical concern; mild curves → physiotherapy + bracing (TLSO); progressive curves > 40–50° → surgical correction (posterior spinal fusion); perioperative concerns include seizure management, difficult airway (macrostomia, mandibular prognathia), and postoperative pain assessment challenges (non-verbal patient)
Joint contractures	Chronic spasticity (especially lower limbs) → shortening of muscle-tendon units → fixed flexion contractures at hips, knees, ankles; exacerbated by limited mobility	Preventive stretching programme; ankle-foot orthoses (AFOs); serial casting; botulinum toxin for focal spasticity; rarely surgical tendon release
Osteoporosis / reduced bone mineral density	Multifactorial: ↓weight-bearing activity, chronic AED use (valproate), possible ↓vitamin D, nutritional factors	Calcium and vitamin D supplementation; encourage weight-bearing activity; monitor with DEXA; consider bisphosphonates in severe cases (specialist decision)
Hip subluxation / dislocation	Spasticity + abnormal gait biomechanics → altered hip joint forces in the growing skeleton	Screen with hip radiograph if clinical concern; orthopaedic referral for progressive subluxation

Complication	Pathophysiological Basis	Management
Feeding difficulty (infancy) ^[1]	Oromotor dysfunction from truncal hypotonia + poor coordination of suck-swallow-breathe sequence → inefficient feeding	Feeding assessment by SLT; positioning optimisation; thickened feeds; nasogastric tube (short-term) or gastrostomy (long-term) if severe
Aspiration and aspiration pneumonia	Dysphagia from oromotor dysfunction → food/liquid enters airway instead of oesophagus; also GORD contributes (see below)	Videofluoroscopic swallow study (VFSS) or fibreoptic endoscopic evaluation of swallowing (FEES) if aspiration suspected; texture modification; positioning; fundoplication if severe GORD
Gastro-oesophageal reflux disease (GORD)	Truncal hypotonia → poor lower oesophageal sphincter tone; supine positioning in non-ambulant children; certain AEDs (benzodiazepines) further relax smooth muscle	PPI therapy (omeprazole 0.5–1 mg/kg/day); positioning (upright after feeds); Nissen fundoplication for severe/refractory cases or recurrent aspiration
Constipation	Hypotonia of GI smooth muscle → reduced peristalsis; reduced mobility; dehydration from poor oral intake; some AEDs (e.g., benzodiazepines) reduce gut motility	Dietary fibre, adequate fluids; osmotic laxatives (macrogol/PEG 0.5–1 g/kg/day or lactulose); stimulant laxatives if needed; disimpaction protocol for faecal loading
Obesity (adolescence/adulthood)	Reduced physical activity; some AEDs promote weight gain (valproate); excessive caloric intake if feeding is unrestricted in older patients	Monitor BMI; dietary counselling; encourage adapted physical activity
Failure to thrive / underweight (infancy/early childhood)	Feeding difficulty → inadequate caloric intake; high metabolic demand from frequent seizures and hyperkinetic movements	Nutritional supplementation; calorie-dense feeds; gastrostomy if oral intake insufficient

The Feeding Paradox in AS

AS patients may experience failure to thrive in infancy (from feeding difficulty) but then develop obesity in adolescence/adulthood (from reduced activity + AED weight gain + unlimited food access). Nutritional management must be age-adapted — addressing undernutrition early and preventing obesity later. Regular growth monitoring using appropriate growth charts is essential.

Complication	Pathophysiological Basis	Impact
Sleep disturbance	↓Endogenous melatonin secretion (UBE3A role in circadian clock regulation); abnormal sleep architecture (↓total sleep time, ↓REM sleep, frequent night-time awakenings) ^[1]	Affects ~80% of AS patients; impacts daytime function, behaviour (increased hyperactivity and irritability when sleep-deprived), seizure threshold (sleep deprivation lowers seizure threshold — creating a vicious cycle), and family wellbeing (caregiver burnout from nocturnal disruption)
Obstructive sleep apnoea (OSA)	Hypotonia of upper airway muscles + possible obesity + midface hypoplasia → upper airway collapse during sleep	May exacerbate seizures and behavioural problems; screen with polysomnography if clinical suspicion (snoring, witnessed apnoeas, daytime somnolence); management: CPAP (difficult compliance in AS), adenotonsillectomy if adenotonsillar hypertrophy

Why sleep matters beyond just tiredness: In epilepsy, sleep deprivation is a well-established seizure precipitant. In AS, the interplay is particularly vicious — poor sleep → more seizures → post-ictal drowsiness disrupting sleep further → more seizures. Breaking this cycle with melatonin and good sleep hygiene is genuinely therapeutic.

Complication	Pathophysiological Basis	Management
Severe challenging behaviour	Hyperactivity, short attention span, impulsivity, self-stimulatory behaviours (hand-flapping, mouthing); frustration from inability to communicate → outbursts, aggression	Structured environment, visual schedules, positive reinforcement; AAC to reduce communicative frustration; avoid sedating medications unless absolutely necessary; no role for stimulants (lower seizure threshold)
Self-injurious behaviour	Frustration, sensory-seeking, or stereotypic behaviour patterns; may also relate to pain (dental, constipation, GORD) that the non-verbal child cannot communicate	Rule out pain sources first; behavioural strategies; environmental modification; rarely low-dose risperidone (with extreme caution — QT prolongation, metabolic effects)
Anxiety (especially in adolescence/adulthood)	May manifest as behavioural regression, increased stereotypies, sleep worsening, or refusal of activities	Rule out medical causes (pain, constipation, seizure change); environmental modification; rarely anxiolytics

Complication	Pathophysiological Basis	Management
Bruxism (teeth grinding)	Very common (~70–80%); mechanism unclear but likely related to central motor circuit dysfunction	Dental mouth guards (compliance may be difficult); regular dental review; may cause significant tooth wear
Widely-spaced teeth, macrostomia ^[1]	Part of the craniofacial dysmorphism; related to mandibular prognathia and abnormal dental development	Orthodontic assessment; dental caries risk may be elevated due to poor oral hygiene (dependence on caregivers), mouth breathing, and sugar-containing medications (liquid AED formulations)
Gingival hyperplasia	If valproate or (incorrectly) phenytoin used → drug-induced gingival overgrowth	Regular dental hygiene; switch AED if significant; surgical gingivectomy rarely needed
Excessive drooling	Oromotor dysfunction → poor saliva management rather than excessive production	Glycopyrrolate; botulinum toxin to salivary glands; surgical options (submandibular duct rerouting or ligation) for severe cases

Complication	Pathophysiological Basis	Management
Strabismus	Abnormal cranial nerve / cortical visual pathway development	Ophthalmology referral; patching, spectacles, or surgical correction
Refractive errors	May be higher prevalence than general population	Regular visual assessment (challenging in non-verbal child — may require specialised paediatric ophthalmology techniques)
Ocular albinism (deletion patients only)	Co-deletion of OCA2 gene → ↓melanin in iris and retina → photosensitivity, nystagmus, ↓visual acuity	Tinted spectacles; low-vision aids

Complication	Pathophysiological Basis
Aspiration pneumonia	Oromotor dysfunction + GORD → chronic microaspiration → recurrent lower respiratory tract infections
Restrictive lung disease	Progressive scoliosis → reduced thoracic cage compliance → ↓lung volumes → respiratory insufficiency (particularly in severely affected adolescents/adults)
Seizure-related apnoea	Generalised tonic-clonic seizures may cause transient central apnoea; prolonged seizures → hypoxia

Life Stage	Key Complications	Surveillance Actions
Infancy (0–1 year)	Feeding difficulty, failure to thrive, early seizures, sleep disturbance	Feeding assessment, growth monitoring, EEG if seizures suspected, sleep history
Early childhood (1–5 years)	Drug-resistant epilepsy (peak severity), status epilepticus, developmental plateau, behavioural challenges	AED optimisation, developmental therapy, EEG monitoring, behavioural support
Later childhood (5–12 years)	Scoliosis onset, constipation, dental problems (bruxism), obesity risk begins, seizure-related injuries	Scoliosis screening, dental care, nutrition counselling, bone health assessment
Adolescence (12–18 years)	Scoliosis progression, puberty management (menstrual management in girls), obesity, AED-related bone disease, transition planning	Spinal radiograph, DEXA, gynaecological input if needed, adult service liaison
Adulthood (> 18 years)	Seizures may improve but rarely resolve; scoliosis stabilises but complications of severe curves persist; osteoporosis; aspiration pneumonia; Parkinsonian features may emerge; lifelong dependence for all ADLs	Ongoing AED review, bone health, respiratory assessment, guardianship, community support, respite care

Parameter	Detail
Life expectancy	Near-normal in many patients with good medical care; reduced in those with severe epilepsy, scoliosis-related respiratory compromise, or aspiration-related complications
Seizure trajectory	Often improve in adolescence/adulthood — may become less frequent and less severe, though rarely resolve completely
Cognitive trajectory	Non-progressive (static encephalopathy); no regression (if regression occurs, reconsider diagnosis or look for superimposed metabolic/infective cause)
Motor trajectory	Some patients achieve independent ambulation (though always ataxic); others remain wheelchair-dependent; spasticity and contractures may worsen without intervention
Quality of life	With appropriate support, many individuals with AS lead fulfilling lives; the happy disposition is genuinely part of their personality, not merely a neurological artefact; families frequently describe their AS children as bringing joy to those around them

High Yield Summary — Complications of Angelman Syndrome

Epilepsy is the most significant medical complication — affects 80–90%; often drug-resistant; peak severity in childhood; risk of status epilepticus and SUDEP ^[1]^[4]
AED-related complications: valproate → hepatotoxicity, bone demineralisation, weight gain, teratogenicity; levetiracetam → behavioural side effects; topiramate → nephrolithiasis, metabolic acidosis
Scoliosis develops in up to 50–70% — screen at every visit; truncal hypotonia → poor paraspinal support ^[1]
Feeding complications: oromotor dysfunction → aspiration risk, GORD, failure to thrive in infancy → obesity in adolescence
Sleep disturbance (~80%) — ↓melatonin; worsens seizures via sleep deprivation; impacts family wellbeing ^[1]
Constipation: hypotonia of GI smooth muscle + reduced mobility + AED effects
Dental: bruxism (~70–80%), widely-spaced teeth, drooling
Osteoporosis: multifactorial (AEDs, immobility, nutrition) — ensure calcium + vitamin D
Behavioural challenges: hyperactivity, self-injury, anxiety — often driven by inability to communicate (use AAC)
Prognosis: near-normal life expectancy with good care; seizures often improve in adulthood; cognition is static (non-progressive); lifelong dependence for ADLs

Active Recall - Complications of Angelman Syndrome

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 498–500) ^[4] Senior notes: Ryan Ho Neurology.pdf (p. 102)

High Yield Summary

Angelman Syndrome — Key Points for Exams

UBE3A gene on 15q11-13 is paternally imprinted in the brain → only maternal copy active in neurons → loss of maternal UBE3A = Angelman syndrome ^[1]^[2]^[3]
Most common mechanism: de novo maternal deletion (~70–75%) ^[1]
Incidence: ~1 in 12,000–20,000; M=F; majority de novo ^[1]
Cardinal features: severe developmental delay, (near-)absence of speech, ataxia, epilepsy (80–90%), happy disposition with unprovoked laughter ^[1]
Craniofacial: microcephaly, brachycephaly, macrostomia, protruding tongue, widely-spaced teeth, prominent chin, deep-set eyes ^[1]
Hypopigmentation of skin/hair/eyes occurs in deletion patients due to co-deletion of OCA2 gene ^[1]
Neurological: truncal hypotonia + limb hypertonia ± hyperreflexia + ataxia → characteristic "puppet-like" gait ^[1]
EEG: high-amplitude rhythmic delta activity, characteristic even before clinical seizures ^[4]
Methylation testing confirms AS diagnosis: only paternal (unmethylated) pattern detected ^[2]
Sister disorder: Prader-Willi syndrome (loss of paternal 15q11-13 contribution) — both share hypotonia, developmental delay, and intellectual disability ^[2]
Molecular mechanism determines: phenotype severity, recurrence risk, and genetic counselling ^[1]^[2]
Seizures may worsen with carbamazepine, vigabatrin, phenytoin — avoid these AEDs in AS

High Yield Summary — Differential Diagnosis of Angelman Syndrome

Closest mimic: Christianson syndrome (X-linked, SLC9A6) — males with Angelman-like phenotype + progressive cerebellar atrophy on MRI
Sister disorder: Prader-Willi syndrome — same locus (15q11-13), opposite parental origin; distinguished by hyperphagia/obesity, hypogonadism, mild-moderate ID, and speech development
Rett syndrome: Distinguished by regression after 6–18 months, hand-wringing stereotypies, breathing irregularities; almost exclusively females
Pitt-Hopkins: Distinguished by episodic hyperventilation → apnoea
Metabolic/neurodegenerative: Distinguished by progressive course and multisystem involvement
Cerebral palsy: Distinguished by perinatal history, structural MRI lesions, absence of specific behavioural phenotype
Key first-line test: Methylation-specific testing at 15q11-13 — confirms AS and excludes PWS simultaneously ^[2]
If methylation normal, proceed to UBE3A sequencing; if both negative, consider Angelman-like panel / WES

High Yield Summary — Diagnosis of Angelman Syndrome

Consensus clinical criteria: 4 consistent features (all must be present) — severe GDD, no speech, ataxia/tremor, happy demeanour with unprovoked laughter ^[1]
Frequent features (> 80%): postnatal microcephaly, seizures (onset < 3 years), characteristic EEG ^[1]^[4]
First-line test: Methylation analysis (MS-MLPA/MS-PCR) — detects ~80% of cases; shows only paternal (unmethylated) pattern in AS ^[2]
If methylation abnormal → determine mechanism: CMA (deletion) → UPD studies → IC analysis
If methylation normal → UBE3A sequencing (detects ~10–20% with point mutations) ^[1]
If all negative → NGS panel / WES for Angelman-like disorders
EEG: high-amplitude 2–3 Hz frontal delta, theta bursts, eye-closure-facilitated epileptiform discharges ^[4]
MRI brain: usually normal; role is to exclude structural/metabolic pathology
Mechanism determines recurrence risk: deletion/UPD < 1%; inherited UBE3A mutation or IC deletion up to 50%
Metabolic screen indicated if progressive course, regression, or atypical systemic features ^[3]^[5]

High Yield Summary — Management of Angelman Syndrome

No cure exists — management is multidisciplinary, symptomatic, and supportive
Seizure management is the most critical aspect:
- First-line: valproate (broad-spectrum) or levetiracetam (if < 2 years or valproate contraindicated)
- Add-on: clobazam, clonazepam, ethosuximide
- Refractory: topiramate, ketogenic diet, vagus nerve stimulation
- AVOID carbamazepine, phenytoin, vigabatrin, tiagabine, gabapentin — all worsen myoclonic/absence seizures ^[1]
Communication: Augmentative and Alternative Communication (AAC) is essential; PECS, communication boards, eye-gaze technology
Sleep: Melatonin is first-line pharmacotherapy (AS patients have ↓endogenous melatonin)
Scoliosis requires regular screening; bracing or surgery for progressive curves ^[1]
Feeding: Oromotor assessment; glycopyrrolate for drooling; constipation management
Genetic counselling: Recurrence risk varies by mechanism — < 1% for de novo deletion/UPD vs up to 50% for inherited UBE3A mutation or IC deletion
Emerging therapy: ASOs targeting UBE3A-ATS to unsilence paternal UBE3A — potentially disease-modifying; in clinical trials
Transition planning to adult services is critical — lifelong condition with ongoing care needs

High Yield Summary — Complications of Angelman Syndrome

Epilepsy is the most significant medical complication — affects 80–90%; often drug-resistant; peak severity in childhood; risk of status epilepticus and SUDEP ^[1]^[4]
AED-related complications: valproate → hepatotoxicity, bone demineralisation, weight gain, teratogenicity; levetiracetam → behavioural side effects; topiramate → nephrolithiasis, metabolic acidosis
Scoliosis develops in up to 50–70% — screen at every visit; truncal hypotonia → poor paraspinal support ^[1]
Feeding complications: oromotor dysfunction → aspiration risk, GORD, failure to thrive in infancy → obesity in adolescence
Sleep disturbance (~80%) — ↓melatonin; worsens seizures via sleep deprivation; impacts family wellbeing ^[1]
Constipation: hypotonia of GI smooth muscle + reduced mobility + AED effects
Dental: bruxism (~70–80%), widely-spaced teeth, drooling
Osteoporosis: multifactorial (AEDs, immobility, nutrition) — ensure calcium + vitamin D
Behavioural challenges: hyperactivity, self-injury, anxiety — often driven by inability to communicate (use AAC)
Prognosis: near-normal life expectancy with good care; seizures often improve in adulthood; cognition is static (non-progressive); lifelong dependence for ADLs

Angelman Syndrome

1. Definition

2. Epidemiology

3. Anatomy and Function: The UBE3A Gene and the 15q11-13 Imprinted Region

3.1 Chromosomal Location

3.2 UBE3A Gene Function

3.3 Why Loss of UBE3A Causes Neurological Disease

3.4 Imprinting Control Region (ICR)

4. Aetiology (Focus on Hong Kong / East Asian Populations)

4.1 Genetic Mechanisms

4.2 Comparing AS with Prader-Willi Syndrome (PWS) — "Sister" Imprinting Disorders

4.3 Hong Kong Considerations

5. Classification

6. Clinical Features

6.1 Overview of Age at Presentation

6.2 Symptoms (What the Parents Report)

A. Developmental Concerns

B. Seizures / Epilepsy

C. Behavioural Features

D. Other Parental Concerns

6.3 Signs (What You Find on Examination)

A. Craniofacial Appearance

B. Neurological Signs

C. EEG Findings (Even Before Clinical Seizures)

D. Growth and Anthropometrics

E. Musculoskeletal Signs

F. Other Signs

6.4 Summary of Clinical Features by Age

6.5 Consensus Clinical Diagnostic Criteria (Williams et al., updated)

7. Relationship to Other Conditions in the Differential

Active Recall - Angelman Syndrome (Definition, Epidemiology, Aetiology, Clinical Features)

References

1. Framework for the Differential Diagnosis

2. Differential Diagnosis by Category

A. "Sister" Imprinting Disorder: Prader-Willi Syndrome (PWS)

B. Genetic Conditions with Severe ID, Absent Speech, and Epilepsy ("Angelman-Like" Phenotypes)

C. Other Chromosomal / Genetic Conditions Presenting with Severe ID and Seizures

D. Metabolic Disorders

E. Acquired Causes of Severe ID with Epilepsy and Movement Disorder

F. Other Conditions to Consider

3. Diagnostic Approach — Mermaid Flowchart

4. Key Differentiating Clinical Clues — Summary Table

5. "Red Flags" That Shift You Away from AS Diagnosis

6. Approach to Confirming/Excluding AS When It Is in the Differential

Active Recall - Differential Diagnosis of Angelman Syndrome

1. Consensus Clinical Diagnostic Criteria

1.1 Consistent Features (Present in 100% of Confirmed Cases)

1.2 Frequent Features (Present in > 80%)

1.3 Associated Features (Present in 20–80%)

2. Molecular Diagnostic Criteria — Confirming the Diagnosis

3. Diagnostic Algorithm — Mermaid Flowchart

4. Investigation Modalities — Detailed Interpretation

4.1 Genetic / Molecular Investigations

A. Methylation-Specific Multiplex Ligation-Dependent Probe Amplification (MS-MLPA)

B. Fluorescence In Situ Hybridisation (FISH)

C. Chromosomal Microarray (CMA) / Array Comparative Genomic Hybridisation (aCGH)

D. UPD Studies (Microsatellite / SNP Analysis)

E. Imprinting Centre (IC) Analysis

F. UBE3A Gene Sequencing (Sanger or NGS)

G. Next-Generation Sequencing Panel / Whole Exome Sequencing (WES)

4.2 Neurophysiology — Electroencephalography (EEG)

4.3 Neuroimaging — MRI Brain

4.4 Metabolic Investigations (to Exclude Metabolic Mimics)

4.5 Other Supportive Investigations

5. Interpreting Test Results — Worked Example

6. Summary of Diagnostic Approach — Key Principles

Active Recall - Diagnostic Criteria, Algorithm, and Investigations for Angelman Syndrome

1. Overview — Management Principles

2. Management Algorithm — Mermaid Flowchart

3. Detailed Treatment Modalities

3.1 Seizure Management — The Most Critical Aspect

A. Why Seizures in AS Are Challenging

B. First-Line Antiepileptic Drugs (AEDs)

C. Second-Line / Add-On AEDs

D. Third-Line / Refractory Options

E. AEDs to AVOID — Critical for Exams

F. Emergency Seizure Management

3.2 Developmental and Behavioural Therapies

A. Speech and Language Therapy (SLT)

B. Physiotherapy (PT) and Occupational Therapy (OT)